Enalapril

Enalapril

Cardiovascular Drugs

Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020

Risk Summary: Enalapril is contraindicated during the 2nd and 3rd Trimesters because the pregnancy experience in humans showed a profound potentiality of teratogenicity and severe fetal toxicity associated with its use during this period.

Trimethylamine N-oxide and ACE inhibitors: fighting a new enemy with an established weapon?

View Article

Journal Information

Published in Biomarkers, 2018

Oliver Danne

The activation of the renin-angiotensin-aldosterone system (RAAS) plays a key role in the development and progression of cardiovascular disease, especially in arterial hypertension, heart failure and coronary artery disease. Angiotensin-converting-enzyme (ACE) inhibitors are a cornerstone in the prevention and treatment of cardiovascular disease and the most used and studied type of renin-angiotensin-aldosterone system (RAAS) blocker. Their benefits are due to their neurohormonal modulatory effects, which have vasodilatory, anti-inflammatory, plaque-stabilizing, antithrombotic and anti-proliferative effects (López-Sendón et al.2004). Enalapril is an established inhibitor of the ACE and was introduced into the market in 1981. Enalapril is a prodrug which undergoes biotransformation to the active metabolite enalaprilat and is used for the treatment of arterial hypertension, diabetic kidney disease, heart failure and for secondary prevention of coronary artery disease.

Explore chapters and articles related to this topic

Cardiovascular Drugs

Trimethylamine N-oxide and ACE inhibitors: fighting a new enemy with an established weapon?